Laura Shawver Sells 97,244 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 97,244 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $13.56, for a total value of $1,318,628.64. Following the transaction, the director now owns 210,346 shares in the company, valued at approximately $2,852,291.76. This represents a 31.61 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Laura Shawver also recently made the following trade(s):

• On Wednesday, December 4th, Laura Shawver sold 14,772 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.75, for a total value of $203,115.00.

ARS Pharmaceuticals Trading Up 6.0 %

SPRY stock traded up $0.81 during midday trading on Wednesday, hitting $14.42. The company’s stock had a trading volume of 974,767 shares, compared to its average volume of 818,810. The company has a market cap of $1.40 billion, a PE ratio of -26.69 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a 12 month low of $5.01 and a 12 month high of $18.51. The firm’s 50-day moving average is $14.80 and its 200-day moving average is $12.15.

Wall Street Analyst Weigh In

SPRY has been the topic of a number of research analyst reports. Raymond James upgraded ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $18.00 to $22.00 in a report on Tuesday, August 13th. William Blair raised ARS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Leerink Partners boosted their price target on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research report on Friday, September 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 price target on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $24.00.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in SPRY. Vanguard Group Inc. raised its stake in ARS Pharmaceuticals by 37.0% during the 1st quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock valued at $29,500,000 after buying an additional 779,969 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of ARS Pharmaceuticals in the 1st quarter worth $172,000. Virtu Financial LLC purchased a new stake in shares of ARS Pharmaceuticals in the 1st quarter worth $206,000. SG Americas Securities LLC increased its stake in shares of ARS Pharmaceuticals by 861.5% in the 2nd quarter. SG Americas Securities LLC now owns 111,592 shares of the company’s stock worth $950,000 after purchasing an additional 99,986 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in ARS Pharmaceuticals by 99.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 139,285 shares of the company’s stock worth $1,185,000 after buying an additional 69,394 shares during the period. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.